
    
      This prospective, non-randomized, observational study will be conducted at 35 centers
      worldwide where the study devices have 3T MR Conditional labeling; up to 110 patients will be
      enrolled, and will satisfy the recent PMCF requirement to maintain the CE mark.
    
  